Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|January 21, 2015
Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancerYuhei Kinehara, Toshiyuki Minami, Takashi Kijima, et al.
Biochemical and Biophysical Research Communications|September 28, 2019
EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrestHirotoshi Ishigaki, Toshiyuki Minami, Osamu Morimura, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2023
Combination therapy with anti-programmed cell death 1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulationAkio Tada, Toshiyuki Minami, Hidemi Kitai, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|September 22, 2009
[The contribution of widely used devices in the diagnosis of peripheral pulmonary lesions in patients presenting with respiratory distress]Motohiro Tamiya, Shinji Sasada, Nobuko Uehara, et al.
FEBS Open Bio|June 18, 2013
Calretinin mediates apoptosis in small cell lung cancer cells expressing tetraspanin CD9Ping He, Hanako Kuhara, Isao Tachibana, et al.
Scientific Reports|September 17, 2013
Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesisToshiyuki Minami, Takashi Kijima, Satoshi Kohmo, et al.
Cancer Science|June 13, 2020
Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesotheliomaDaisuke Horio, Toshiyuki Minami, Hidemi Kitai, et al.
Cancer Science|January 30, 2026
Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical OutcomesKinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort studyYuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
Pageof 7